Ascent Pediatrics Primsol trimethoprim solution launch expected in 1997 -- company IPO.
ASCENT PEDIATRICS PRIMSOL TRIMETHOPRIM SOLUTION LAUNCH PLANNED FOR 1997, the company states in an April 25 initial public offering prospectus. Ascent Pediatrics has an NDA pending for Primsol as an alternative to trimethoprim/ sulfamethoxazole in the treatment of acute otitis media in children. In January, FDA's Anti-Infective Drug Products Division "notified Ascent that it recommended approval of the company's NDA for Primsol solution for the treatment of AOM in children age six months to 12 years, with a label reflecting that Primsol solution would not be a product for first line therapy for this indication," the prospectus states. Based on that communication, "Ascent expects to receive marketing approval from FDA...in the first half of 1997" following completion of labeling discussions.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth